Speaker


Beth DelGiacco | VP, Corporate Communications & Investor Relations, argenx

Beth DelGiacco is the Vice President, Corporate Communications & Investor Relations at argenx and joined the company in 2018. In this role, Beth is responsible for implementing and executing all internal and external communications strategies to our key stakeholders. 

Prior to joining argenx, Beth was a Vice President at Stern Investor Relations, an investor relations firm offering biotechnology companies strategic and client-specific advisory services. She has worked in managing institutional investor relationships for over 15 years, previously on the healthcare team at Guidepoint Global and the Neurology team at Global Data. She holds a Master’s degree in Public Health from Columbia University and a Bachelor’s degree in Chemistry and Spanish from the University of Rochester. She also completed a post-baccalaureate fellowship at the National Institutes of Health.


argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Twitter, and Instagram.

Powered by:
Hyphen Projects   

Let's connect:           
Book a ticket
FAQ
Contact Us
Privacy Policy
Terms & Conditions 
Chamber of Commerce: 32110979
VAT no: NL8184.34.491.B01
          
 
 

                                    

Keep me informed Download our event app


© Copyright 2023 by Hyphen Projects